Prime Medicine (PRME) Free Cash Flow (2021 - 2026)
Prime Medicine posted quarterly Free Cash Flow of -$42.9 million for Q1 2026, up 16.29% year-on-year from -$36.9 million in Q1 2025, and down 29.57% on a QoQ basis from -$33.1 million in Q4 2025.
Prime Medicine (PRME) has 6 years of Free Cash Flow data on file, last reported at -$42.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 16.29% year-over-year to -$42.9 million; the trailing twelve-month figure through Mar 2026 stood at -$154.3 million (down 46.6% YoY), and the FY2025 full-year result was -$162.7 million, down 31.17% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$42.9 million, down from -$33.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $15.2 million in Q4 2024 and bottomed at -$70.0 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$39.1 million (2025), against an average of -$37.4 million.
- The widest annual swing landed in 2024, when Free Cash Flow soared 133.26%; it then tumbled 317.93% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$30.8 million in 2022, then tumbled by 48.33% to -$45.7 million in 2023, then soared by 133.26% to $15.2 million in 2024, then plunged by 317.93% to -$33.1 million in 2025, then declined by 29.57% to -$42.9 million in 2026.
- The last three Free Cash Flow figures came in at -$42.9 million (Q1 2026), -$33.1 million (Q4 2025), and -$39.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -42.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.92 Mn |
| Mar 31, 2026 | -42.92 Mn |
| Dec 31, 2025 | -33.13 Mn |
| Dec 31, 2025 | -33.13 Mn |
| Sep 30, 2025 | -39.13 Mn |
| Sep 30, 2025 | -39.13 Mn |
| Jun 30, 2025 | -39.14 Mn |
| Jun 30, 2025 | -39.14 Mn |
| Mar 31, 2025 | -51.28 Mn |
| Mar 31, 2025 | -51.28 Mn |
| Dec 31, 2024 | 15.20 Mn |
| Dec 31, 2024 | 15.20 Mn |
| Sep 30, 2024 | -25.67 Mn |
| Sep 30, 2024 | -25.67 Mn |
| Jun 30, 2024 | -43.52 Mn |
| Jun 30, 2024 | -43.52 Mn |
| Mar 31, 2024 | -70.03 Mn |
| Mar 31, 2024 | -70.03 Mn |
| Dec 31, 2023 | -45.70 Mn |
| Dec 31, 2023 | -45.70 Mn |
| Sep 30, 2023 | -45.34 Mn |
| Sep 30, 2023 | -45.34 Mn |
| Jun 30, 2023 | -38.93 Mn |
| Jun 30, 2023 | -38.93 Mn |
| Mar 31, 2023 | -44.16 Mn |
| Mar 31, 2023 | -44.16 Mn |
| Dec 31, 2022 | -30.81 Mn |
| Dec 31, 2022 | -30.81 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Jun 30, 2022 | -21.12 Mn |
| Jun 30, 2022 | -21.12 Mn |
| Mar 31, 2022 | -52.48 Mn |
| Mar 31, 2022 | -52.48 Mn |
| Dec 31, 2021 | -10.17 Mn |
| Dec 31, 2021 | -10.17 Mn |